Introduction
]. For instance, it has been reported that Old world monkey 93 A3G proteins contribute to restrict lentiviral transmission among these species 94 (Compton et al., 2014; Compton and Emerman, 2013) . 95 96
SIVgor was first discovered from the fecal samples of wild GORs, which 97 were obtained in remote forest regions in Cameroon in 2007 (Van Heuverswyn et 98 al., 2006 . A following study revealed that SIVgor is phylogenetically related to 99 HIV-1 groups O and P (D'arc et al., 2015) , suggesting that SIVgor is the ancestral 100 virus of these HIV-1s in the human population. Moreover, a phylogenetic analysis 101 deduced that SIVgor emerged from the leap of SIVcpzPtt from CPZ to GOR 102 ).
104
The molecular interactions between HIV-1 Vif and HU A3 proteins are well 105 established [reviewed in (Harris and Dudley, 2015) ]. Also, the functional and 106 evolutionary relationships between SIVcpzPtt Vif and HU A3 proteins have been 107
investigated (Letko et al., 2013; Sato et al., 2018; Zhang et al., 2017) . However, the 108 evolutionary episodes of great ape lentiviruses through GOR, namely, the 109 emergence of (i) SIVgor from SIVcpzPtt; and (ii) HIV-1OP from SIVgor, have not 110 been fully investigated. Moreover, the functional and evolutionary association of 111 great ape lentiviral Vif with their host A3 proteins remains unclear. In this study, we 112 focus on the antiviral effects of great ape A3 proteins including GOR A3s and their 113 antagonistic mechanisms by great ape lentiviral Vif proteins. To the best of our 114 knowledge, this is the first report suggesting that a great ape A3 protein potently 115 restricts the cross-species leap of great ape lentiviruses and illustrates the 116 evolutionary scenario of great ape lentiviruses via the interaction of great ape A3 117 proteins. 118 Figure 1A illustrates a phylogenetic tree of vif genes of great ape 121 lentiviruses. This phylogenetic tree indicates that HIV-1M and HIV-1N form clusters 122 with SIVcpzPtt, while HIV-1O and HIV-1P are together with SIVgor. Consistent with 123 previous reports, it is suggested that HIV-1M and HIV-1N originated from SIVcpzPtt 124 (Keele et al., 2006) , while HIV-1O and HIV-1P are derived from SIVgor (D'arc et al., 125 2015) ( Figure 1B) . 126
Results

119
GOR A3G restricts SIVcpzPtt infection 120
To address the possibility that great ape A3G can be a factor restricting 127 cross-species transmission of great ape lentiviruses, we set out to analyze the 128 antiviral activity of great ape A3G. We co-transfected the expression plasmids of 129 great ape (HU, CPZ and GOR) A3G with an infectious molecular clone (IMC) of 130 vif-deleted HIV-1. All great ape A3Gs exhibited comparably strong and 131
dose-dependent antiviral effects (Figure S1B and S1C). 132
To assess the ability of lentiviral Vif to counteract host A3G, the expression 133 plasmid for HU A3G was co-transfected together with the Vif expression plasmids 134
and an IMC of vif-deleted HIV-1. As shown in Figure 1C , all lentiviral Vifs including 135 HIV-1MNOP, SIVcpzPtt and SIVgor degraded HU A3G and impaired the 136 incorporation of HU A3G into the released virions. Also, in the presence of HU A3G, 137 the viral infectivity was rescued by all lentiviral Vifs tested in this study ( Figure 1D) . 138
These findings suggest that HU A3G does not restrict cross-species transmission of 139 SIVs from CPZ and GOR to HU. In sharp contrast, we found that GOR A3G was 140 antagonized by SIVgor Vif but not by SIVcpzPtt Vif (Figures 1E and 1F ). These 141 findings strongly suggested that the antiviral activity of GOR A3G had to be 142 overcome for cross-species transmission of SIVcpzPtt from CPZ to GOR. 143
144
M16E mutation confers anti-GOR A3G ability on SIVcpzPtt Vif 145
To investigate how SIVgor acquired the ability to counteract GOR A3G, we 146 next performed gain-of-function experiments based on SIVcpzPtt Vif (strain MB897). 147
We first prepared four chimeric Vif mutants of SIVcpzPtt MB897 and SIVgor 148 CP2139 (chimeras A-D; Figure 2A ) and evaluated their ability to counteract GOR 149 A3G-mediated antiviral action using the cell-based single-round infection assays. 150
As shown in Figure 2B , SIVgor CP2139 Vif as well as chimera A Vif overcame the 151 at position 16. In addition to the M16E mutant, the M16D mutant of MB897 Vif 185 counteracted the GOR A3G-mediated antiviral effect, while the M16A and M16Q 186 mutants did not ( Figure 2H ). Taken together, these results suggested that acquiring 187 an acidic residue at position 16 is sufficient to counteract GOR A3G-mediated 188 antiviral effect. 189
190
GOR A3D and A3F poorly exhibit antiviral effect 191
It is known that the DRMR motif, residues positioned between 14-17 in Vif, 192 are crucial to counteract HU A3D and A3F (Russell et al., 2009; Sato et al., 2014) . 
Vif DRMR motif is distortedly evolved in GOR 205
We next assessed the conservation of the DRMR motif in great ape 206 lentiviral Vif. As shown in Figure 4A , this motif is highly conserved in HIV-1M, 207
HIV-1N, SIVcpzPtt and SIVcpzPts, another group of SIVcpz in a subspecies of 208 chimpanzee (eastern chimpanzee; Pan troglodytes schweinfurthii). In contrast, this 209 domain is altered in HIV-1O, HIV-1P and SIVgor ( Figure 4A) . Moreover, the 210 molecular phylogenetic analysis on the Vif DRMR motif indicated that this motif in 211 HIV-1O, HIV-1P and SIVgor forms separated clusters to HIV-1M, HIV-1N, 212
SIVcpzPtt and SIVcpzPts with higher bootstrap values ( Figure S3A ). Since the 213 YRHHY motif positioned between 40-44 in Vif, which is responsible for A3G 214 counteraction (Russell et al., 2009; Sato et al., 2014) , is highly conserved in all 215 great ape lentiviruses (Figure 4A ), these findings suggest that the Vif DRMR motif 216 may be less functionally constrained. 217
The loss of the DRMR motif in the Vifs of HIV-1O, HIV-1P and SIVgor 218 raised the possibility that these Vifs are unable to counteract A3D and A3F from HU 219 and GOR. To address this issue, the expression plasmids for HU A3D or A3F were 220 co-transfected together with the Vif expression plasmids and an IMC of vif-deleted 221 HIV-1. As shown in Figures 4B and 4C , it was surprising that the all Vifs tested 222 including those from HIV-1O, HIV-1P and SIVgor counteracted both HU A3D and 223 A3F. These Vifs also counteracted GOR A3D and A3F (Figure S3B and S3C) . 224
These findings (Figures 4A-4C In the present study, we demonstrated that HU A3D, A3F, and A3G are 238 counteracted by all great ape lentiviral Vifs tested in this study. Our results are 239 consistent with previous observations that SIVcpz and 240
SIVgor ) are able to replicate in in vitro human CD4 + T-cell 241 culture. Moreover, SIVcpz efficiently expands in a hematopoietic stem 242 cell-transplanted humanized mouse model (Sato et al., 2018; Yamada et al., 2018) . 243
Taken together with our findings, these observations suggest that HU A3 proteins 244 may not have been a barrier to SIV transmission from CPZ and GOR to HU. In 245 contrast, SIVcpzPtt Vif was incapable of antagonizing the GOR A3G-mediated 246 antiviral effect. Here we demonstrated that an amino acid substitution at position 16 247 of SIVcpzPtt Vif is sufficient to acquire the ability to counteract GOR A3G. Our 248 findings suggest that GOR A3G restriction activity had to be overcome for 249 transmission from of SIVcpzPtt from CPZ to GOR. To the best of our knowledge, 250 this is the first report providing evidence that a great ape A3 protein plays a crucial 251 role in restricting the leap of great ape lentivirus between different host species and 252 how exactly primate lentiviruses overcame the hurdle mediated by host antiviral A3 253 protein. Furthermore, we revealed that the antiviral effects of GOR A3D and A3F 254 are relatively weaker than those of HU and CPZ counterparts and that the Vif 255 DRMR motif, which is important to counteract HU A3D and A3F (Russell et al., 256 2009; Sato et al., 2014) , has been lost in SIVgor and related HIV-1s (groups O and 257 P). These findings suggest that the evolutionary process of great ape lentiviruses 258 leading to HIV-1 in HU was uniquely skewed via SIV infection in GOR. 283 Surprisingly, the amino acid residue responsible for the counteraction of 284 GOR A3G was located in the Vif DRMR motif, which is required for degradation of 285 HU A3D and A3F (Russell et al., 2009; Sato et al., 2014) . Additionally, the Vif 286 DRMR motif was less conserved in SIVgor and related HIV-1 (groups O and P), 287 while this motif was highly conserved in SIVcpzPtt and related HIV-1 (groups M and 288 N). Moreover, the phylogenetic tree of the Vif DRMR motif revealed that SIVgor 289 forms a cluster with HIV-1 groups O and P. These findings indicated that the Vif 290 DRMR motif, in particular, has been lost when GOR was the host species. In this 291 regard, we demonstrated that the antiviral activity of GOR A3D and A3F is relatively 292 weaker than that of HU and CPZ counterparts. Taken together with these findings, 293 the skewed evolution of the Vif DRMR motif in GOR might be permitted due to the 294 selection pressure mediated by A3D and A3F being relaxed in GOR. Furthermore, 295 although the vif nucleotide sequence similarity between SIVcpzPtt and SIVcpzPts, 296 which is classified as the outgroup of HIV-1, SIVcpzPtt and SIVgor, was relatively 297 low (p-distance between SIVcpzPtt vif and SIVcpzPts vif = 0.347 ± 0.016), the 298 DRMR motif is highly conserved in SIVcpzPts and the phylogenetic tree of the Vif 299 DRMR motif indicated that SIVcpzPts forms a cluster with SIVcpzPtt and related 300 HIV-1s. These observations further suggest that the loss of the Vif DRMR motif may 301 be specific to SIVgor and related viruses. 302
303
Although SIVgor and related HIV-1s lost the Vif DRMR motif in GOR, 304 these Vifs showed the ability to counteract A3D and A3F from GOR and HU. These 305 findings suggest that the loss of the DRMR motif resulted in the acquisition of novel 306 domain(s) to counteract A3D and A3F and to maintain Vif's integrity. In addition to 307 the distorted evolution in the Vif DRMR motif, previous studies suggested that other 308 viral antagonists, Vpu and Nef, have uniquely evolved in GOR: based on the 309 findings that HIV-1M Vpu but not SIVcpzPtt Vpu counteracts HU tetherin (Sauter et 310 al., 2009) , it is implied that gain of anti-HU tetherin activity by Vpu is important for 311 cross-species lentiviral transmission from CPZ to HU [reviewed in (Kirchhoff, 2010) ]. Vif and A3 in GOR has uniquely affected the evolutionary episode of great ape 323 lentiviruses. We elucidated how SIVcpzPtt Vif overcame a species barrier mediated 324 by GOR A3G. This is the first report explaining how great ape lentiviral Vif 325 dismantled the hurdle mediated by new host A3 that potently impedes 326 cross-species transmission of great ape lentiviruses, which has naturally occurred 327 in Africa. 328
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TZM-bl assay (F). 492
For Western blotting, the input of cell lysate was standardized to TUBA, and 493 representative results are shown. For TZM-bl assay, the percentage of the value 494 without HU A3G (D) and the raw value (relative infectivity) determined by TZM-bl 495 assay (F) are shown. The mean values of nine independent experiments ± SEM are 496
shown, and statistically significant differences (P < 0.05) versus "no Vif" are shown 497 by asterisks. 498
See also Figure S1 and Table S1 . Figure S2A . 503 (B-D) Determination of the amino acid residue of SIV Vif that is responsible to 504 counteract GOR A3G. HEK293T cells were co-transfected with pNL4-3Δvif and the 505 expression plasmids for GOR A3G (10 or 50 ng; the plasmid amount was 506 normalized by empty vector) and the indicated Vif derivatives. Cells and 507 supernatants were harvested at two days post-transfection and were used for 508
Western blotting and TZM-bl assay. 509 (E and F) Multi-round replication assay. The infectious viruses of SIVcpzPtt MB897 510 WT, M16E and E2X (vif deleted) derivatives were prepared as described in 511 STAR*METHODS and were inoculated into parental SupT11-CCR5 cells or the 512 SupT11-CCR5 stably expressing GOR A3G (see also Figure S2B ) at MOI 0.1. (E) 513
Culture supernatant was harvested per two days and the amount of infectious 514 viruses was measured by using TZM-bl cells. (F) Area under the curve (AUC) of 515 respective virus infection culture is shown. 516 (G) Importance of M16E substitution in other SIVcpzPtt strains to counteract GOR 517 A3G.
518
(H) Importance of acidic residue at position 16 of SIVcpzPtt to counteract GOR 519 A3G. 520
In (G) and (H), HEK293T cells were co-transfected with pNL4-3Δvif and the 521 expression plasmids for GOR A3G and the indicated Vif strains and derivatives. 522
Cells and supernatants were harvested at two days post-transfection and were 523 used for Western blotting (left) and TZM-bl assay (right).
524
For Western blotting, the input of cell lysate was standardized to TUBA, and 525 representative results are shown. For TZM-bl assay, the percentage of the value 526 without GOR A3G is shown. The mean values of nine independent experiments ± 527 SEM are shown. Statistically significant differences (P < 0.05) versus "CP2139" 528 (B-D, G and H) or "M16E" (E and F) are shown by red asterisks. NS, no statistical 529 significance.
530
See also Figure S2 . 531 532 Figure 3 . Poor antiviral activity of GOR A3D and A3F 533 Antiviral activity of great ape A3D (A and B) and A3F (C and D). HEK293T cells 534
were co-transfected with pNL4-3Δvif and the different amounts of expression 535 plasmids for great ape A3D and A3F (0, 50, 100, and 200 ng; the plasmid amount 536 was normalized by empty vector). Cells and supernatants were harvested at two 537 days post-transfection and were used for Western blotting (A and C) and TZM-bl 538 assay (B and D). For Western blotting, the input of cell lysate was standardized to 539 TUBA, and representative results are shown. For TZM-bl assay, the infectivity value 540 without A3 was set to 100%. 541 542 analysis.
548
(B and C) Activity of primate lentiviral Vif against HU A3D and A3F. HEK293T cells 549
were co-transfected with pNL4-3Δvif and the expression plasmids for HU A3 and 550 indicated Vif. Cells and supernatants were harvested at two days post-transfection 551 and were used for Western blotting (top) and TZM-bl assay (bottom).
552
(D) Scheme of HIV-1M JRCSF Vif derivatives used in this study.
553
(E and F) Vif's activity against HU A3D and A3F. HEK293T cells were 554 co-transfected with pNL4-3Δvif and the expression plasmids for HU A3D (E) or A3F 555 (F) and indicated Vif. Cells and supernatants were harvested at two days 556 post-transfection and were used for Western blotting (left) and TZM-bl assay (right).
557
For Western blotting, the input of cell lysate was standardized to TUBA, and 558
representative results are shown. For TZM-bl assay, the percentage of the value 559 without HU A3 is shown. The mean values of six independent experiments ± SEM 560 are shown, and statistically significant differences (P < 0.05) versus "no Vif" are 561
shown by asterisks.
562
See also Figure S3 . 563 564
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Further information and requests for resources and reagents may be directed to 566 and will be fulfilled by the Lead Contact, Kei Sato (ksato@ims.u-tokyo.ac.jp) . 567 antibodies. To prepare the SupT11-CCR5 cells stably expressing GOR A3G 582 (SupT11-CCR5-GOR A3G), a GOR A3G expression plasmid was transfected into 583 SupT11-CCR5 cells using the Neon Transfection system (Thermo Fisher Scientific). 584
568
EXPERIMENTAL MODEL AND SUBJECT DETAILS 569
Cells and Viruses
The transfected cells were selected with Puromycin (InvivoGen; 0.5 ng/ml) and the 585 expression of GOR A3G in the selected cell clone was analyzed by Western blotting 586 using anti-HU A3G antibody ( Figure S2C) . Parental SupT11-CCR5 and 587
SupT11-CCR5-GOR A3G cells were maintained in RPMI1640 (Sigma) containing 588
FCS and antibiotics. 589
HEK293T cells were transfected using PEI Max (Polysciences) according 590 to the manufacturer's protocol. Basically, the expression plasmids for flag-tagged 591 great ape A3D (HU, 50 ng; GOR, 200 ng), A3F (HU, 50 ng; GOR, 200 ng) or A3G 592 (HU, 10 ng; GOR, 50 ng) were co-transfected with pNL4-3Δvif (500 ng), an 593 infectious molecular clone (IMC) of vif-deleted HIV-1M strain NL4-3 (Sato et al., 594 harvested and were respectively used for TZM-bl assay and Western blotting as 597 described below. For the preparation of infectious viruses, the IMCs (1,000 ng) 598 were transfected into HEK293T cells. At two days post-transfection, the culture 599 supernatants were harvested, centrifuged, and then filtered through a 600 0.45-µm-pore-size filter. To titrate virus infectivity, TZM-bl assay was performed as 601 described below. 602
603
METHOD DETAILS 604
Molecular Phylogenetic 605
The vif open reading frame (ORF) sequences (listed in aligned by using Clustal W implemented in MEGA 7 software (Kumar et al., 2016) . 609
Maximum-likelihood phylogenetic trees ( Figures 1A, S1A and S3A) were 610 constructed using MEGA 7 software (Kumar et al., 2016) . The logoplot of Vif amino 611 acid sequence is constructed using WebLogo 3 (http://weblogo.threeplusone.com) 612 and the residues at positions 14-17 (DRMR motif) and 40-44 (YRHHY motif) are 613 shown in Figure 4A . 614
615
Expression Plasmids 616
To construct the expression plasmids for flag-tagged great ape A3s, pcDNA3.1 617 plasmid (Thermo Fisher Scientific) was used as a backbone. The expression 618 plasmids for flag-tagged HU A3D, A3F and A3G were used in our previous study 619 (Nakano et al., 2017b) . To construct the expression plasmids for flag-tagged CPZ 620 and GOR A3s, the ORFs of CPZ A3D (JN247642), CPZ A3F (XM_525658), CPZ 621 A3G (NM_001009001), GOR A3D (JN247649), GOR A3F (JN247640) and GOR 622 A3G (AY639868) were synthesized by the GeneArt gene synthesis service (Thermo 623
Fisher Scientific). The obtained DNA fragments were inserted into EcoRV-NotI (for 624 A3D and A3F) or EcoRI-XhoI (for A3G) sites of pcDNA3.1 plasmid (Thermo Fisher 625 Scientific). To construct the expression plasmids for HA-tagged lentiviral Vifs, 626 pDON-AI plasmid (Takara) was used as a backbone. The expression plasmid for 627 the HA-tagged Vifs of HIV-1M NL4-3 (M19921), SIVcpzPtt MB897 (JN835461) and 628 SIVcpzPtt MT145 (JN835462) were used in our previous study (Sato et al., 2018) . 629 Yamada et al., 2018) . Briefly, 10 µl of virus supernatant was inoculated into TZM-bl 663 cells in 96-well plate (Nunc), and the β-galactosidase activity was measured by 664 using the Galacto-Star mammalian reporter gene assay system (Thermo Fisher 665 Scientific) and a 2030 ARVO X multi-label counter instrument (PerkinElmer) 666 according to the manufacturers' procedure. The relative infectivity was determined 667 by relative light unit of this assay. 668 669
Multi-Round Virus Infection 670
The virus supernatant of SIVcpzPtt MB897 WT, M16E and E2X (vif-deleted) 671 derivatives were inoculated into SupT11-CCR5 (parental) and SupT11-CCR5-GOR 672 A3G cells at multiplicity of infection (MOI) 0.1. The culture supernatant was 673 harvested every two days and the amount of infectious viruses was measured by 674 TZM-bl assay. 675
676
QUANTIFICATION AND STATISTICAL ANALYSIS 677
Data analyses were performed using GraphPad Prism software. The data are 678 presented as averages ± SEM. Statistically significant differences were determined 679 by Student's t test. Statistical details can be found directly in the figures or in the 680 corresponding figure legends. 681 Table S2 This study N/A Primers for construction of SIVcpzPtt Vif derivatives, see Table S3 This study N/A Primers for construction of HIV-1M JRCSF Vif derivatives, see Table S4 This study N/A Primers for construction of SIVcpzPtt MBV897 IMC derivatives, see Table S5 This study N/A
PEI
Recombinant DNA
Plasmid: pNL4-3∆vif (IMC of vif-deleted HIV-1 group M strain NL4-3) (Sato et al., 2014) Genbank accession no. M19921
Plasmid: pJRCSF (HIV-1 group M strain JRCSF) (Koyanagi et al., 1987) Genbank accession no. M38429
Plasmid: pDJO0131 (HIV-1 group N strain DJO0131) (Sauter et al., 2012) 
